The scoop on Walmart's latest health venture
Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and
Today in healthcare news: Walmart's quietly building a startup that wants to use data to help customers make healthier choices, a senior living chain is requiring employees to get shots, and Verve's building a gene-editing treatment for heart disease.
Walmartis building a new health venture through its incubation arm Store No.8, Business Insider has learned.
- The venture, which doesn't have a name yet, will aim to help shoppers make healthier choices based on their own shopping data.
- It builds on Walmart's healthcare business, which includes clinics and pharmacies.
A major chain of senior living facilities will require more than 10,000 workers to get COVID-19 shots
- Atria Senior Living, a large operator of independent living, assisted living, and other
senior livingfacilities, is requiring more than 10,000 US employees to get the COVID-19 vaccine.
- Atria CEO John Moore told Business Insider that requiring the vaccine is "the responsible thing to do" to stop the spread of the coronavirus among staff and residents.
- Several other long-term care companies told Business Insider they are not mandating the coronavirus vaccine.
- Employers can require staff to give COVID-19 shots without running afoul of the law, according to federal guidance, and more employers are expected to follow in Atria's footsteps.
Verve is gearing up to test a gene-editing treatment that could cure heart disease. The CEO shares his 3-step vision for the one-and-done heart treatment.
- A buzzy Cambridge, Massachusetts biotech is advancing its research on a gene-editing treatment for heart disease.
Verve TherapeuticsCEO Sekar Kathiresan outlined the company's three-stage strategy to ultimately cure heart disease.
- Verve's first treatment candidate uses a next-generation gene-editing tool called base-editing to change a single letter in a person's genetic code. That edit will lower levels of bad cholesterol, the company hopes.
More stories we're reading:
- One of digital health's only dedicated early-stage venture firms just raised $200 million for its second fund. Here's how founder Lynne Chou O'Keefe plans to spend it. (Business Insider)
- Uber and Lyft are pushing for a role in vaccine rollout (The Wall Street Journal)
- Answers to your 24 most burning questions about the coronavirus vaccine, from side effects and costs to when you'll be able to get one (Business Insider)
- One of Intarcia's key investors wrote down its stake former unicorn Intarcia (Stat News)
- Sansera Engineering IPO — How to check allotment status, listing date and more
- The collapse of Evergrande, one of China’s largest home developers, is “not a Lehman moment” but the fear may haunt steel and metal stocks in India
- Amazon is investigating its lawyers for allegedly bribing Indian government officials
- Noise ropes in Taapsee Pannu as its brand ambassador for smart wearables
- Online fantasy gaming startup earns almost five times Dhoni's Chennai Super Kings
- Samsung's first F-series phone with 5G support, Galaxy F42, to launch soon
- 2021 Yamaha R15 V4.0, R15M, Aerox 155 launched in India — all you need to know
- Tara Sutaria to be the face of Olay India's premium skincare range